Login Register Cart 0
General Review Article

原发性震颤神经化学的最新进展

卷 27, 期 10, 2020

页: [1690 - 1710] 页: 21

弟呕挨: 10.2174/0929867325666181112094330

价格: $65

摘要

背景：原发性震颤（ET）的病理生理和神经化学机制尚不完全清楚，因为仅报告了几项验尸研究，并且缺乏针对这种疾病的良好实验模型。 目的：本综述的主要目的是更新有关ET神经化学特征的数据。已经描述了某些儿茶酚胺系统，多巴胺能，5-羟色胺能，GABA能，去甲肾上腺素能和肾上腺素能系统的改变，并且是该修订的目的。 方法：为此，我们对ET患者（验尸或体内）的神经递质或神经调节系统（儿茶酚胺，γ-氨基丁酸或GABA，兴奋性氨基酸，腺苷，T型钙通道）的变化进行了文献综述。 ）或类似ET的实验模型。 结果和结论：关于ET神经化学的最一致的数据与GABA能和谷氨酸能系统有关，腺苷和多巴胺能和肾上腺素能系统的贡献较小，而没有足够的证据表明其他神经递质系统在ET中有明确的作用。用T型钙通道拮抗剂，大麻素1受体，鞘氨醇1-磷酸受体激动剂和间隙连接阻滞剂实现的啮齿动物模型中由harmaline引起的震颤的改善表明这些结构在ET发病机理中的潜在作用。

关键词: 原发性震颤，神经化学，GABA，谷氨酸，多巴胺，去甲肾上腺素，肾上腺素，5-羟色胺，腺苷，T型钙通道。

« Previous
[1]
Rajput, A.H.; Rozdilsky, B.; Kish, S.; Hornykiewicz, O. Parkinson’s disease association with essential tremor. Mov. Disord., 1990, 5(Suppl. 1), 14.
[2]
Shill, H.A.; Adler, C.H.; Beach, T.G.; Lue, L.F.; Caviness, J.N.; Sabbagh, M.N.; Sue, L.I.; Walker, D.G. Brain biochemistry in autopsied patients with essential tremor. Mov. Disord., 2012, 27(1), 113-117.
[http://dx.doi.org/10.1002/mds.24004] [PMID: 22038525]
[3]
Lee, M.S.; Kim, Y.D. Im, J.H.; Kim, H.J.; Rinne, J.O.; Bhatia, K.P. 123I-IPT brain study in essential tremor and Parkinson’s disease. Neurology, 1999, 52, 1422-1426.
[http://dx.doi.org/10.1212/WNL.52.7.1422] [PMID: 10227629]
[4]
Plotkin, M.; Amthauer, H.; Klaffke, S.; Kühn, A.; Lüdemann, L.; Arnold, G.; Wernecke, K.D.; Kupsch, A.; Felix, R.; Venz, S. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J. Neural Transm. (Vienna), 2005, 112(5), 677-692.
[http://dx.doi.org/10.1007/s00702-004-0208-x] [PMID: 15375677]
[5]
Isaias, I.U.; Marotta, G.; Hirano, S.; Canesi, M.; Benti, R.; Righini, A.; Tang, C.; Cilia, R.; Pezzoli, G.; Eidelberg, D.; Antonini, A. Imaging essential tremor. Mov. Disord., 2010, 25(6), 679-686.
[http://dx.doi.org/10.1002/mds.22870] [PMID: 20437537]
[6]
Benamer, T.S.; Patterson, J.; Grosset, D.G.; Booij, J.; de Bruin, K.; van Royen, E.; Speelman, J.D.; Horstink, M.H.; Sips, H.J.; Dierckx, R.A.; Versijpt, J. Decoo. D; Van Der Linden, C.; Hadley, D.M.; Doder, M.; Lees, A.J.; Costa, D.C.; Gacinovic, S.; Oertel, W.H.; Pogarel,l O.; Hoeffken, H.; Joseph. K.; Tatsch, K.; Schwarz, J.; Ries, V. Accurate differentiation of parkinsonism and essential tremor using visual assessment of 123I-FP-CIT-SPECT imaging: the 123I-FP-CIT-SPECT study group. Mov. Disord., 2000, 15, 503-510.
[http://dx.doi.org/10.1002/1531-8257(200005)15:3<503:AID-MDS1013>3.0.CO;2-V]
[7]
Wang, J.; Jiang, Y.P.; Liu, X.D.; Chen, Z.P.; Yang, L.Q.; Liu, C.J.; Xiang, J.D.; Su, H.L. 99mTc-TRODAT-1 SPECT study in early Parkinson’s disease and essential tremor. Acta Neurol. Scand., 2005, 112(6), 380-385.
[http://dx.doi.org/10.1111/j.1600-0404.2005.00517.x] [PMID: 16281920]
[8]
Antonini, A.; Moresco, R.M.; Gobbo, C.; De Notaris, R.; Panzacchi, A.; Barone, P.; Calzetti, S.; Negrotti, A.; Pezzoli, G.; Fazio, F. The status of dopamine nerve terminals in Parkinson’s disease and essential tremor: a PET study with the tracer [11-C]FE-CIT. Neurol. Sci., 2001, 22(1), 47-48.
[http://dx.doi.org/10.1007/s100720170040] [PMID: 11487195]
[9]
Breit, S.; Reimold, M.; Reischl, G.; Klockgether, T.; Wüllner, U. [(11)C]d-threo-methylphenidate PET in patients with Parkinson’s disease and essential tremor. J. Neural Transm. (Vienna), 2006, 113(2), 187-193.
[http://dx.doi.org/10.1007/s00702-005-0311-7] [PMID: 15959851]
[10]
Parkinson Study Group. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology, 2000, 55(10), 1540-1547.
[http://dx.doi.org/10.1212/WNL.55.10.1540] [PMID: 11094111]
[11]
Di Giuda, D.; Camardese, G.; Bentivoglio, A.R.; Cocciolillo, F.; Guidubaldi, A.; Pucci, L.; Bruno, I.; Janiri, L.; Giordano, A.; Fasano, A. Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39(12), 1937-1948.
[http://dx.doi.org/10.1007/s00259-012-2232-7] [PMID: 22976499]
[12]
Waln, O.; Wu, Y.; Perlman, R.; Wendt, J.; Van, A.K.; Jankovic, J. Dopamine transporter imaging in essential tremor with and without parkinsonian features. J. Neural Transm. (Vienna), 2015, 122(11), 1515-1521.
[http://dx.doi.org/10.1007/s00702-015-1419-z] [PMID: 26133163]
[13]
Barbagallo, G.; Arabia, G.; Morelli, M.; Nisticò, R.; Novellino, F.; Salsone, M.; Rocca, F.; Quattrone, A.; Caracciolo, M.; Sabatini, U.; Cherubini, A.; Quattrone, A. Thalamic neurometabolic alterations in tremulous Parkinson’s disease: A preliminary proton MR spectroscopy study. Parkinsonism Relat. Disord., 2017, 43, 78-84.
[http://dx.doi.org/10.1016/j.parkreldis.2017.07.028] [PMID: 28774469]
[14]
Brooks, D.J.; Playford, E.D.; Ibanez, V.; Sawle, G.V.; Thompson, P.D.; Findley, L.J.; Marsden, C.D. Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. Neurology, 1992, 42(8), 1554-1560.
[http://dx.doi.org/10.1212/WNL.42.8.1554] [PMID: 1641153]
[15]
Asenbaum, S.; Pirker, W.; Angelberger, P.; Bencsits, G.; Pruckmayer, M.; Brücke, T. [123I]beta-CIT and SPECT in essential tremor and Parkinson’s disease. J. Neural Transm. (Vienna), 1998, 105(10-12), 1213-1228.
[http://dx.doi.org/10.1007/s007020050124] [PMID: 9928890]
[16]
Gerasimou, G.; Costa, D.C.; Papanastasiou, E.; Bostanjiopoulou, S.; Arnaoutoglou, M.; Moralidis, E.; Aggelopoulou, T.; Gotzamani-Psarrakou, A. SPECT study with I-123-Ioflupane (DaTSCAN) in patients with essential tremor. Is there any correlation with Parkinson’s disease? Ann. Nucl. Med., 2012, 26(4), 337-344.
[http://dx.doi.org/10.1007/s12149-012-0577-4] [PMID: 22382608]
[17]
Isaias, I.U.; Canesi, M.; Benti, R.; Gerundini, P.; Cilia, R.; Pezzoli, G.; Antonini, A. Striatal dopamine transporter abnormalities in patients with essential tremor. Nucl. Med. Commun., 2008, 29(4), 349-353.
[http://dx.doi.org/10.1097/MNM.0b013e3282f4d307] [PMID: 18317299]
[18]
Ceravolo, R.; Antonini, A.; Volterrani, D.; Rossi, C.; Kiferle, L.; Frosini, D.; Lucetti, C.; Isaias, I.U.; Benti, R.; Murri, L.; Bonuccelli, U. Predictive value of nigrostriatal dysfunction in isolated tremor: a clinical and SPECT study. Mov. Disord., 2008, 23(14), 2049-2054.
[http://dx.doi.org/10.1002/mds.22259] [PMID: 18759337]
[19]
Coria, F.; Gimenez-Garcia, M.; Samaranch, L.; Mora, F.J.; Sampol-Bas, C.; Pastor, P. Nigrostriatal dopaminergic function in subjects with isolated action tremor. Parkinsonism Relat. Disord., 2012, 18(1), 49-53.
[http://dx.doi.org/10.1016/j.parkreldis.2011.08.025] [PMID: 21917500]
[20]
Pirker, W.; Djamshidian, S.; Asenbaum, S.; Gerschlager, W.; Tribl, G.; Hoffmann, M.; Brücke, T. Progression of dopaminergic degeneration in Parkinson’s disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov. Disord., 2002, 17(1), 45-53.
[http://dx.doi.org/10.1002/mds.1265] [PMID: 11835438]
[21]
Schwartz, M.; Groshar, D.; Inzelberg, R.; Hocherman, S. Dopamine-transporter imaging and visuo-motor testing in essential tremor, practical possibilities for detection of early stage Parkinson’s disease. Parkinsonism Relat. Disord., 2004, 10(6), 385-389.
[http://dx.doi.org/10.1016/j.parkreldis.2004.03.004] [PMID: 15261882]
[22]
Lenman, J.A.; Turnbull, M.J.; Reid, A.; Fleming, A.M. Urinary monoamine metabolite excretion in disorders of movement. Effects of amantadine and levodopa. J. Neurol. Sci., 1977, 32(2), 219-225.
[http://dx.doi.org/10.1016/0022-510X(77)90237-4] [PMID: 874521]
[23]
Pellicano, C.; Buttarelli, F.R.; Circella, A.; Tiple, D.; Giovannelli, M.; Benincasa, D.; Colosimo, C.; Pontieri, F.E. Dopamine transporter immunoreactivity in peripheral blood lymphocytes discriminates Parkinson’s disease from essential tremor. J. Neural Transm. (Vienna), 2007, 114(7), 935-938.
[http://dx.doi.org/10.1007/s00702-006-0623-2] [PMID: 17260170]
[24]
Schwartz, M.; Badarny, S.; Gofman, S.; Hocherman, S. Visuomotor performance in patients with essential tremor. Mov. Disord., 1999, 14(6), 988-993.
[http://dx.doi.org/10.1002/1531-8257(199911)14:6<988:AID-MDS1012>3.0.CO;2-M] [PMID: 10584674]
[25]
Jiménez-Jiménez, F.J.; Rubio, L.; Alonso-Navarro, H.; Calleja, M.; Pilo-de-la-Fuente, B.; Plaza-Nieto, J.F.; Benito-León, J.; García-Ruiz, P.J.; Agúndez, J.A. Impairment of rapid repetitive finger movements and visual reaction time in patients with essential tremor. Eur. J. Neurol., 2010, 17(1), 152-159.
[http://dx.doi.org/10.1111/j.1468-1331.2009.02784.x] [PMID: 19765055]
[26]
Pedrosa, D.J.; Nelles, C.; Maier, F.; Eggers, C.; Burghaus, L.; Fink, G.R.; Wittmann, M.; Timmermann, L. Time reproduction deficits in essential tremor patients. Mov. Disord., 2016, 31(8), 1234-1240.
[http://dx.doi.org/10.1002/mds.26630] [PMID: 27091412]
[27]
Lucotte, G.; Lagarde, J.P.; Funalot, B.; Sokoloff, P. Linkage with the Ser9Gly DRD3 polymorphism in essential tremor families. Clin. Genet., 2006, 69(5), 437-440.
[http://dx.doi.org/10.1111/j.1399-0004.2006.00600.x] [PMID: 16650084]
[28]
Jeanneteau, F.; Funalot, B.; Jankovic, J.; Deng, H.; Lagarde, J.P.; Lucotte, G.; Sokoloff, P. A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc. Natl. Acad. Sci. USA, 2006, 103(28), 10753-10758.
[http://dx.doi.org/10.1073/pnas.0508189103] [PMID: 16809426]
[29]
García-Martín, E.; Martínez, C.; Alonso-Navarro, H.; Benito-León, J.; Puertas, I.; Rubio, L.; López-Alburquerque, T.; Agúndez, J.A.; Jiménez-Jiménez, F.J. Dopamine receptor D3 (DRD3) genotype and allelic variants and risk for essential tremor. Mov. Disord., 2009, 24(13), 1910-1915.
[http://dx.doi.org/10.1002/mds.22518] [PMID: 19645064]
[30]
Jiménez-Jiménez, F.J.; Alonso-Navarro, H.; García-Martín, E.; Lorenzo-Betancor, O.; Pastor, P.; Agúndez, J.A. Update on genetics of essential tremor. Acta Neurol. Scand., 2013, 128(6), 359-371.
[http://dx.doi.org/10.1111/ane.12148] [PMID: 23682623]
[31]
Mao, X.; Wang, T.; Liu, M.; Chang, X.; Li, N.; Gu, Y.; Zhao, D.; Liao, Q.; Peng, R. Meta-analysis of the influence of DRD3 Ser9Gly variant on susceptibility for essential tremor. J. Clin. Neurosci., 2013, 20(12), 1644-1649.
[http://dx.doi.org/10.1016/j.jocn.2013.03.023] [PMID: 24054403]
[32]
Kuhlenbäumer, G.; Hopfner, F.; Deuschl, G. Genetics of essential tremor: meta-analysis and review. Neurology, 2014, 82(11), 1000-1007.
[http://dx.doi.org/10.1212/WNL.0000000000000211] [PMID: 24532269]
[33]
Jiménez-Jiménez, F.J.; García-Martín, E.; Alonso-Navarro, H.; Lorenzo-Betancor, O.; Ortega-Cubero, S.; Pastor, P.; Calleja, M.; Agúndez, J.A. A family study of DRD3 rs6280, SLC1A2 rs3794087 and MAPT rs1052553 variants in essential tremor. Neurol. Res., 2016, 38(10), 880-887.
[http://dx.doi.org/10.1080/01616412.2016.1210355] [PMID: 27456607]
[34]
Ossowska, K.; Głowacka, U.; Kosmowska, B.; Wardas, J. Apomorphine enhances harmaline-induced tremor in rats. Pharmacol. Rep., 2015, 67(3), 435-441.
[http://dx.doi.org/10.1016/j.pharep.2014.11.008] [PMID: 25933950]
[35]
Herceg, M.; Nagy, F.; Pál, E.; Janszky, J.; Késmárky, I.; Komoly, S.; Kovács, N. Pramipexole may be an effective treatment option in essential tremor. Clin. Neuropharmacol., 2012, 35(2), 73-76.
[http://dx.doi.org/10.1097/WNF.0b013e31824687bf] [PMID: 22318193]
[36]
Kosmowska, B.; Wardas, J.; Głowacka, U.; Ananthan, S.; Ossowska, K. Pramipexole at a low dose induces beneficial effect in the harmaline-induced model of essential tremor in rats. CNS Neurosci. Ther., 2016, 22(1), 53-62.
[http://dx.doi.org/10.1111/cns.12467] [PMID: 26459182]
[37]
Rajput, A.H.; Hornykiewicz, O.; Deng, Y.; Birdi, S.; Miyashita, H.; Macaulay, R. Increased noradrenaline levels in essential tremor brain. Neurology, 2001, 56(Suppl. 3), A302.
[38]
Barkhatova, V.P.; Ivanova-Smolenskaia, I.A. [Catecholamine metabolism in essential tremor]. Zh. Nevropatol. Psikhiatr. Im. S. S. Korsakova, 1990, 90(3), 10-14.
[PMID: 2163146]
[39]
van Hilten, J.J.; van Dijk, J.G.; Dunnewold, R.J.; van der Velde, E.A.; Kemp, B.; van Brummelen, P.; van der Krogt, J.A.; Roos, R.A.; Buruma, O.J. Diurnal variation of essential and physiological tremor. J. Neurol. Neurosurg. Psychiatry, 1991, 54(6), 516-519.
[http://dx.doi.org/10.1136/jnnp.54.6.516] [PMID: 1880513]
[40]
Tapiador, M.J.; Pérez López-Fraile, I.; López-López, A. Temblor esencial: una revisión sobre sus mecanismos patogénicos. Rev. Neurol., 1998, 27(160), 1059-1065.
[http://dx.doi.org/10.33588/rn.27160.98212] [PMID: 9951036]
[41]
Lee, P.H.; Kim, J.W.; Bang, O.Y.; Joo, I.S.; Yoon, S.N.; Huh, K. Cardiac 123I-MIBG scintigraphy in patients with essential tremor. Mov. Disord., 2006, 21(8), 1235-1238.
[http://dx.doi.org/10.1002/mds.20908] [PMID: 16671077]
[42]
Marsden, C.D.; Foley, T.H.; Owen, D.A.L.; McAllister, R.G. Peripheral beta-adrenergic receptors concerned with tremor. Clin. Sci., 1967, 33(1), 53-65.
[PMID: 6059304]
[43]
Jefferson, D.; Jenner, P.; Marsden, C.D. beta-Adrenoreceptor antagonists in essential tremor. J. Neurol. Neurosurg. Psychiatry, 1979, 42(10), 904-909.
[http://dx.doi.org/10.1136/jnnp.42.10.904] [PMID: 512665]
[44]
Young, R.R.; Growdon, J.H.; Shahani, B.T. Beta-adrenergic mechanisms in action tremor. N. Engl. J. Med., 1975, 293(19), 950-953.
[http://dx.doi.org/10.1056/NEJM197511062931902] [PMID: 1178003]
[45]
Leigh, P.N.; Marsden, C.D.; Twomey, A.; Jefferson, D. beta-Adrenoceptor antagonists and essential tremor. Lancet, 1981, 1(8229), 1106.
[http://dx.doi.org/10.1016/S0140-6736(81)92276-5] [PMID: 6112475]
[46]
Teräväinen, H.; Larsen, T.A. Adrenergic beta-receptor sensitivity in essential tremor. J. Neurol. Neurosurg. Psychiatry, 1984, 47(11), 1216-1218.
[http://dx.doi.org/10.1136/jnnp.47.11.1216] [PMID: 6094733]
[47]
Koller, W.C. Tradozone in essential tremor. Probe of serotoninergic mechanisms. Clin. Neuropharmacol., 1989, 12(2), 134-137.
[http://dx.doi.org/10.1097/00002826-198904000-00009] [PMID: 2655897]
[48]
Gironell, A.; Figueiras, F.P.; Pagonabarraga, J.; Herance, J.R.; Pascual-Sedano, B.; Trampal, C.; Gispert, J.D. Gaba and serotonin molecular neuroimaging in essential tremor: a clinical correlation study. Parkinsonism Relat. Disord., 2012, 18(7), 876-880.
[http://dx.doi.org/10.1016/j.parkreldis.2012.04.024] [PMID: 22595620]
[49]
Abdulrahman, A.A.; Faisal, K.; Meshref, A.A.; Arshaduddin, M. Low-dose acute vanillin is beneficial against harmaline-induced tremors in rats. Neurol. Res., 2017, 39(3), 264-270.
[http://dx.doi.org/10.1080/01616412.2016.1275456] [PMID: 28095756]
[50]
Zoethout, R.W.; Iannone, R.; Bloem, B.R.; Palcza, J.; Murphy, G.; Chodakewitz, J.; Buntinx, A.; Gottesdiener, K.; Marsilio, S.; Rosen, L.; van Dyck, K.; Louis, E.D.; Cohen, A.F.; Schoemaker, R.C.; Tokita, S.; Sato, N.; Koblan, K.S.; Hargreaves, R.H.; Renger, J.; van Gerven, J.M. The effects of a novel histamine-3 receptor inverse agonist on essential tremor in comparison to stable levels of alcohol. J. Psychopharmacol. (Oxford), 2012, 26(2), 292-302.
[http://dx.doi.org/10.1177/0269881111398685] [PMID: 21335358]
[51]
Ledesma, M.C.; García-Martín, E.; Alonso-Navarro, H.; Martínez, C.; Jiménez-Jiménez, F.J.; Benito-León, J.; Puertas, I.; Rubio, L.; López-Alburquerque, T.; Agúndez, J.A. The nonsynonymous Thr105Ile polymorphism of the histamine N-methyltransferase is associated to the risk of developing essential tremor. Neuromolecular Med., 2008, 10(4), 356-361.
[http://dx.doi.org/10.1007/s12017-008-8040-3] [PMID: 18543121]
[52]
Keeling, B.H.; Vilariño-Güell, C.; Soto-Ortolaza, A.I.; Ross, O.A.; Uitti, R.J.; Rajput, A.; Wszolek, Z.K.; Farrer, M.J. Histamine N-methyltransferase Thr105Ile is not associated with Parkinson’s disease or essential tremor. Parkinsonism Relat. Disord., 2010, 16(2), 112-114.
[http://dx.doi.org/10.1016/j.parkreldis.2009.08.011] [PMID: 19773194]
[53]
Pahapill, P.A.; Levy, R.; Dostrovsky, J.O.; Davis, K.D.; Rezai, A.R.; Tasker, R.R.; Lozano, A.M. Tremor arrest with thalamic microinjections of muscimol in patients with essential tremor. Ann. Neurol., 1999, 46(2), 249-252.
[http://dx.doi.org/10.1002/1531-8249(199908)46:2<249:AID-ANA15>3.0.CO;2-C] [PMID: 10443891]
[54]
Tariq, M.; Arshaduddin, M.; Biary, N.; Al Moutaery, K.; Al Deeb, S. Baclofen attenuates harmaline induced tremors in rats. Neurosci. Lett., 2001, 312(2), 79-82.
[http://dx.doi.org/10.1016/S0304-3940(01)02166-8] [PMID: 11595339]
[55]
de Haas, S.L.; Zoethout, R.W.; Van Dyck, K.; De Smet, M.; Rosen, L.B.; Murphy, M.G.; Gottesdiener, K.M.; Schoemaker, R.C.; Cohen, A.F.; van Gerven, J.M. The effects of TPA023, a GABAAα2,3 subtype-selective partial agonist, on essential tremor in comparison to alcohol. J. Psychopharmacol. (Oxford), 2012, 26(2), 282-291.
[http://dx.doi.org/10.1177/0269881111415731] [PMID: 21890585]
[56]
Málly, J.; Stone, T.W. The effect of theophylline on essential tremor: the possible role of GABA. Pharmacol. Biochem. Behav., 1991, 39(2), 345-349.
[http://dx.doi.org/10.1016/0091-3057(91)90190-D] [PMID: 1946576]
[57]
Málly, J.; Baranyi, M.; Vizi, E.S. Change in the concentrations of amino acids in CSF and serum of patients with essential tremor. J. Neural Transm. (Vienna), 1996, 103(5), 555-560.
[http://dx.doi.org/10.1007/BF01273153] [PMID: 8811501]
[58]
Paris-Robidas, S.; Brochu, E.; Sintes, M.; Emond, V.; Bousquet, M.; Vandal, M.; Pilote, M.; Tremblay, C.; Di Paolo, T.; Rajput, A.H.; Rajput, A.; Calon, F. Defective dentate nucleus GABA receptors in essential tremor. Brain, 2012, 135(Pt 1), 105-116.
[http://dx.doi.org/10.1093/brain/awr301] [PMID: 22120148]
[59]
Luo, C.; Rajput, A.H.; Robinson, C.A.; Rajput, A. Gamma-aminobutyric acid (GABA)-B receptor 1 in cerebellar cortex of essential tremor. J. Clin. Neurosci., 2012, 19(6), 920-921.
[http://dx.doi.org/10.1016/j.jocn.2011.11.001] [PMID: 22321358]
[60]
Boecker, H.; Weindl, A.; Brooks, D.J.; Ceballos-Baumann, A.O.; Liedtke, C.; Miederer, M.; Sprenger, T.; Wagner, K.J.; Miederer, I. GABAergic dysfunction in essential tremor: an 11C-flumazenil PET study. J. Nucl. Med., 2010, 51(7), 1030-1035.
[http://dx.doi.org/10.2967/jnumed.109.074120] [PMID: 20554735]
[61]
Louis, E.D.; Hernandez, N.; Dyke, J.P.; Ma, R.E.; Dydak, U. In vivo dentate nucleus gamma-aminobutyric acid concentration in essential tremor vs. controls. Cerebellum, 2018, 17(2), 165-172.
[http://dx.doi.org/10.1007/s12311-017-0891-4] [PMID: 29039117]
[62]
Kralic, J.E.; Criswell, H.E.; Osterman, J.L.; O’Buckley, T.K.; Wilkie, M.E.; Matthews, D.B.; Hamre, K.; Breese, G.R.; Homanics, G.E.; Morrow, A.L. Genetic essential tremor in gamma-aminobutyric acidA receptor alpha1 subunit knockout mice. J. Clin. Invest., 2005, 115(3), 774-779.
[http://dx.doi.org/10.1172/JCI200523625] [PMID: 15765150]
[63]
Deng, H.; Xie, W.J.; Le, W.D.; Huang, M.S.; Jankovic, J. Genetic analysis of the GABRA1 gene in patients with essential tremor. Neurosci. Lett., 2006, 401(1-2), 16-19.
[http://dx.doi.org/10.1016/j.neulet.2006.02.066] [PMID: 16530959]
[64]
García-Martín, E.; Martínez, C.; Alonso-Navarro, H.; Benito-León, J.; Lorenzo-Betancor, O.; Pastor, P.; Puertas, I.; Rubio, L.; López-Alburquerque, T.; Agúndez, J.A.; Jiménez-Jiménez, F.J. Gamma-aminobutyric acid (GABA) receptor rho (GABRR) polymorphisms and risk for essential tremor. J. Neurol., 2011, 258(2), 203-211.
[http://dx.doi.org/10.1007/s00415-010-5708-z] [PMID: 20820800]
[65]
García-Martín, E.; Martínez, C.; Alonso-Navarro, H.; Benito-León, J.; Lorenzo-Betancor, O.; Pastor, P.; Puertas, I.; Rubio, L.; López-Alburquerque, T.; Agúndez, J.A.; Jiménez-Jiménez, F.J. Gamma-aminobutyric acid GABRA4, GABRE, and GABRQ receptor polymorphisms and risk for essential tremor. Pharmacogenet. Genomics, 2011, 21(7), 436-439.
[http://dx.doi.org/10.1097/FPC.0b013e328345bec0] [PMID: 21422964]
[66]
Thier, S.; Kuhlenbäumer, G.; Lorenz, D.; Nothnagel, M.; Nebel, A.; Christensen, K.; Schreiber, S.; Deuschl, G.; Klebe, S. GABA(A) receptor- and GABA transporter polymorphisms and risk for essential tremor. Eur. J. Neurol., 2011, 18(8), 1098-1100.
[http://dx.doi.org/10.1111/j.1468-1331.2010.03308.x] [PMID: 21749575]
[67]
Liu, X.; Hernandez, N.; Kisselev, S.; Floratos, A.; Sawle, A.; Ionita-Laza, I.; Ottman, R.; Louis, E.D.; Clark, L.N. Identification of candidate genes for familial early-onset essential tremor. Eur. J. Hum. Genet., 2016, 24(7), 1009-1015.
[http://dx.doi.org/10.1038/ejhg.2015.228] [PMID: 26508575]
[68]
Tio, M.; Wen, R.; Lim, Y.L.; Wang, H.; Ling, S.C.; Zhao, Y.; Tan, E.K. FUS-linked essential tremor associated with motor dysfunction in Drosophila. Hum. Genet., 2016, 135(11), 1223-1232.
[http://dx.doi.org/10.1007/s00439-016-1709-z] [PMID: 27395408]
[69]
Chuang, W.L.; Huang, Y.Z.; Lu, C.S.; Chen, R.S. Reduced cortical plasticity and GABAergic modulation in essential tremor. Mov. Disord., 2014, 29(4), 501-507.
[http://dx.doi.org/10.1002/mds.25809] [PMID: 24449142]
[70]
Lee, M.; Cheng, M.M.; Lin, C.Y.; Louis, E.D.; Faust, P.L.; Kuo, S.H. Decreased EAAT2 protein expression in the essential tremor cerebellar cortex. Acta Neuropathol. Commun., 2014, 2, 157.
[http://dx.doi.org/10.1186/s40478-014-0157-z] [PMID: 25391854]
[71]
Wang, J.; Kelly, G.C.; Tate, W.J.; Li, Y.S.; Lee, M.; Gutierrez, J.; Louis, E.D.; Faust, P.L.; Kuo, S.H. Excitatory Amino acid transporter expression in the essential tremor dentate nucleus and cerebellar cortex: A postmortem study. Parkinsonism Relat. Disord., 2016, 32, 87-93.
[http://dx.doi.org/10.1016/j.parkreldis.2016.09.003] [PMID: 27624392]
[72]
Lin, C.Y.; Louis, E.D.; Faust, P.L.; Koeppen, A.H.; Vonsattel, J.P.; Kuo, S.H. Abnormal climbing fibre-Purkinje cell synaptic connections in the essential tremor cerebellum. Brain, 2014, 137(Pt 12), 3149-3159.
[http://dx.doi.org/10.1093/brain/awu281] [PMID: 25273997]
[73]
Louis, E.D.; Shungu, D.C.; Chan, S.; Mao, X.; Jurewicz, E.C.; Watner, D. Metabolic abnormality in the cerebellum in patients with essential tremor: a proton magnetic resonance spectroscopic imaging study. Neurosci. Lett., 2002, 333(1), 17-20.
[http://dx.doi.org/10.1016/S0304-3940(02)00966-7] [PMID: 12401550]
[74]
Pagan, F.L.; Butman, J.A.; Dambrosia, J.M.; Hallett, M. Evaluation of essential tremor with multi-voxel magnetic resonance spectroscopy. Neurology, 2003, 60(8), 1344-1347.
[http://dx.doi.org/10.1212/01.WNL.0000065885.15875.0D] [PMID: 12707440]
[75]
Louis, E.D.; Shungu, D.C.; Mao, X.; Chan, S.; Jurewicz, E.C. Cerebellar metabolic symmetry in essential tremor studied with 1H magnetic resonance spectroscopic imaging: implications for disease pathology. Mov. Disord., 2004, 19(6), 672-677.
[http://dx.doi.org/10.1002/mds.20019] [PMID: 15197706]
[76]
Barbagallo, G.; Arabia, G.; Novellino, F.; Nisticò, R.; Salsone, M.; Morelli, M.; Rocca, F.; Quattrone, A.; Caracciolo, M.; Sabatini, U.; Cherubini, A.; Quattrone, A. Increased glutamate + glutamine levels in the thalamus of patients with essential tremor: A preliminary proton MR spectroscopic study. Parkinsonism Relat. Disord., 2018, 47, 57-63.
[http://dx.doi.org/10.1016/j.parkreldis.2017.11.345] [PMID: 29203059]
[77]
Manto, M.; Laute, M.A. A possible mechanism for the beneficial effect of ethanol in essential tremor. Eur. J. Neurol., 2008, 15(7), 697-705.
[http://dx.doi.org/10.1111/j.1468-1331.2008.02150.x] [PMID: 18445025]
[78]
Rahimi Shourmasti, F.; Goudarzi, I.; Lashkarbolouki, T.; Abrari, K.; Elahdadi Salmani, M.; Goudarzi, A. Effects of riluzole on harmaline induced tremor and ataxia in rats: biochemical, histological and behavioral studies. Eur. J. Pharmacol., 2012, 695(1-3), 40-47.
[http://dx.doi.org/10.1016/j.ejphar.2012.08.014] [PMID: 22975288]
[79]
Vaziri, Z.; Abbassian, H.; Sheibani, V.; Haghani, M.; Nazeri, M.; Aghaei, I.; Shabani, M. The therapeutic potential of Berberine chloride hydrate against harmaline-induced motor impairments in a rat model of tremor. Neurosci. Lett., 2015, 590, 84-90.
[http://dx.doi.org/10.1016/j.neulet.2015.01.078] [PMID: 25643620]
[80]
Ossowska, K.; Wardas, J.; Berghauzen-Maciejewska, K.; Głowacka, U.; Kuter, K.; Pilc, A.; Zorn, S.H.; Doller, D. Lu AF21934, a positive allosteric modulator of mGlu4 receptors, reduces the harmaline-induced hyperactivity but not tremor in rats. Neuropharmacology, 2014, 83, 28-35.
[http://dx.doi.org/10.1016/j.neuropharm.2014.03.018] [PMID: 24726309]
[81]
Thier, S.; Lorenz, D.; Nothnagel, M.; Poremba, C.; Papengut, F.; Appenzeller, S.; Paschen, S.; Hofschulte, F.; Hussl, A.C.; Hering, S.; Poewe, W.; Asmus, F.; Gasser, T.; Schöls, L.; Christensen, K.; Nebel, A.; Schreiber, S.; Klebe, S.; Deuschl, G.; Kuhlenbäumer, G. Polymorphisms in the glial glutamate transporter SLC1A2 are associated with essential tremor. Neurology, 2012, 79(3), 243-248.
[http://dx.doi.org/10.1212/WNL.0b013e31825fdeed] [PMID: 22764253]
[82]
Jiménez-Jiménez, F.J.; Alonso-Navarro, H.; García-Martín, E.; Agúndez, J.A. SLC1A2 rs3794087 variant and risk for essential tremor: a systematic review and meta-analysis. Pharmacogenet. Genomics, 2015, 25(11), 564-568.
[http://dx.doi.org/10.1097/FPC.0000000000000171] [PMID: 26313486]
[83]
Cheng, Y.; Mao, C.Y.; Liu, Y.T.; Li, F.; Yang, J.; Liu, H.; Zhang, C.; Wang, Y.L.; Wu, J.; Shi, C.H.; Xu, Y.M. Analysis of variant rs3794087 in SLC1A2 and Parkinson’s disease in a Chinese Han population: A case-control study and meta-analysis. Neurosci. Lett., 2018, 666, 165-168.
[http://dx.doi.org/10.1016/j.neulet.2017.12.045] [PMID: 29275184]
[84]
Bekar, L.; Libionka, W.; Tian, G.F.; Xu, Q.; Torres, A.; Wang, X.; Lovatt, D.; Williams, E.; Takano, T.; Schnermann, J.; Bakos, R.; Nedergaard, M. Adenosine is crucial for deep brain stimulation-mediated attenuation of tremor. Nat. Med., 2008, 14(1), 75-80.
[http://dx.doi.org/10.1038/nm1693] [PMID: 18157140]
[85]
Chang, S.Y.; Kim, I.; Marsh, M.P.; Jang, D.P.; Hwang, S.C.; Van Gompel, J.J.; Goerss, S.J.; Kimble, C.J.; Bennet, K.E.; Garris, P.A.; Blaha, C.D.; Lee, K.H. Wireless fast-scan cyclic voltammetry to monitor adenosine in patients with essential tremor during deep brain stimulation. Mayo Clin. Proc., 2012, 87(8), 760-765.
[http://dx.doi.org/10.1016/j.mayocp.2012.05.006] [PMID: 22809886]
[86]
Kosmowska, B.; Ossowska, K.; Głowacka, U.; Wardas, J. Tremorolytic effect of 5′-chloro-5′-deoxy-(±)-ENBA, a potent and selective adenosine A1 receptor agonist, evaluated in the harmaline-induced model in rats. CNS Neurosci. Ther., 2017, 23(5), 438-446.
[http://dx.doi.org/10.1111/cns.12692] [PMID: 28371468]
[87]
Park, Y.G.; Park, H.Y.; Lee, C.J.; Choi, S.; Jo, S.; Choi, H.; Kim, Y.H.; Shin, H.S.; Llinas, R.R.; Kim, D. Ca(V)3.1 is a tremor rhythm pacemaker in the inferior olive. Proc. Natl. Acad. Sci. USA, 2010, 107(23), 10731-10736.
[http://dx.doi.org/10.1073/pnas.1002995107] [PMID: 20498062]
[88]
Handforth, A.; Homanics, G.E.; Covey, D.F.; Krishnan, K.; Lee, J.Y.; Sakimura, K.; Martin, F.C.; Quesada, A. T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor. Neuropharmacology, 2010, 59(6), 380-387.
[http://dx.doi.org/10.1016/j.neuropharm.2010.05.012] [PMID: 20547167]
[89]
Chang, K.Y.; Park, Y.G.; Park, H.Y.; Homanics, G.E.; Kim, J.; Kim, D. Lack of CaV3.1 channels causes severe motor coordination defects and an age-dependent cerebellar atrophy in a genetic model of essential tremor. Biochem. Biophys. Res. Commun., 2011, 410(1), 19-23.
[http://dx.doi.org/10.1016/j.bbrc.2011.05.082] [PMID: 21621520]
[90]
Stefansson, H.; Steinberg, S.; Petursson, H.; Gustafsson, O.; Gudjonsdottir, I.H.; Jonsdottir, G.A.; Palsson, S.T.; Jonsson, T.; Saemundsdottir, J.; Bjornsdottir, G.; Böttcher, Y.; Thorlacius, T.; Haubenberger, D.; Zimprich, A.; Auff, E.; Hotzy, C.; Testa, C.M.; Miyatake, L.A.; Rosen, A.R.; Kristleifsson, K.; Rye, D.; Asmus, F.; Schöls, L.; Dichgans, M.; Jakobsson, F.; Benedikz, J.; Thorsteinsdottir, U.; Gulcher, J.; Kong, A.; Stefansson, K. Variant in the sequence of the LINGO1 gene confers risk of essential tremor. Nat. Genet., 2009, 41(3), 277-279.
[http://dx.doi.org/10.1038/ng.299] [PMID: 19182806]
[91]
Jiménez-Jiménez, F.J.; García-Martín, E.; Lorenzo-Betancor, O.; Pastor, P.; Alonso-Navarro, H.; Agúndez, J.A. LINGO1 and risk for essential tremor: results of a meta-analysis of rs9652490 and rs11856808. J. Neurol. Sci., 2012, 317(1-2), 52-57.
[http://dx.doi.org/10.1016/j.jns.2012.02.030] [PMID: 22425540]
[92]
Kuo, S.H.; Tang, G.; Louis, E.D.; Ma, K.; Babji, R.; Balatbat, M.; Cortes, E.; Vonsattel, J.P.; Yamamoto, A.; Sulzer, D.; Faust, P.L. Lingo-1 expression is increased in essential tremor cerebellum and is present in the basket cell pinceau. Acta Neuropathol., 2013, 125(6), 879-889.
[http://dx.doi.org/10.1007/s00401-013-1108-7] [PMID: 23543187]
[93]
Delay, C.; Tremblay, C.; Brochu, E.; Paris-Robidas, S.; Emond, V.; Rajput, A.H.; Rajput, A.; Calon, F. Increased LINGO1 in the cerebellum of essential tremor patients. Mov. Disord., 2014, 29(13), 1637-1647.
[http://dx.doi.org/10.1002/mds.25819] [PMID: 24531928]
[94]
Agúndez, J.A.; Jiménez-Jimenez, F.J.; Alonso-Navarro, H.; García-Martín, E. The potential of LINGO-1 as a therapeutic target for essential tremor. Expert Opin. Ther. Targets, 2015, 19(8), 1139-1148.
[http://dx.doi.org/10.1517/14728222.2015.1028360] [PMID: 25862159]
[95]
Hedera, P. Emerging strategies in the management of essential tremor. Ther. Adv. Neurol. Disorder., 2017, 10(2), 137-148.
[http://dx.doi.org/10.1177/1756285616679123] [PMID: 28382111]
[96]
Abbassian, H.; Whalley, B.J.; Sheibani, V.; Shabani, M. Cannabinoid type 1 receptor antagonism ameliorates harmaline-induced essential tremor in rat. Br. J. Pharmacol., 2016, 173(22), 3196-3207.
[http://dx.doi.org/10.1111/bph.13581] [PMID: 27545646]
[97]
Abbassian, H.; Esmaeili, P.; Tahamtan, M.; Aghaei, I.; Vaziri, Z.; Sheibani, V.; Whalley, B.J.; Shabani, M. Cannabinoid receptor agonism suppresses tremor, cognition disturbances and anxiety-like behaviors in a rat model of essential tremor. Physiol. Behav, 2016, 164(Pt A), 314-320.
[http://dx.doi.org/10.1016/j.physbeh.2016.06.013] [PMID: 27317835]
[98]
Dahmardeh, N.; Asadi-Shekaari, M.; Arjmand, S.; Kalantaripour, T.; Basiri, M.; Shabani, M. Modulation of sphingosine-1-phosphate receptor ameliorates harmaline-induced essential tremor in rat. Neurosci. Lett., 2017, 653, 376-381.
[http://dx.doi.org/10.1016/j.neulet.2017.06.015] [PMID: 28627375]
[99]
Stroh, M.A.; Winter, M.K.; Swerdlow, R.H.; McCarson, K.E.; Zhu, H. Loss of NCB5OR in the cerebellum disturbs iron pathways, potentiates behavioral abnormalities, and exacerbates harmaline-induced tremor in mice. Metab. Brain Dis., 2016, 31(4), 951-964.
[http://dx.doi.org/10.1007/s11011-016-9834-x] [PMID: 27188291]
[100]
Martin, F.C.; Handforth, A. Carbenoxolone and mefloquine suppress tremor in the harmaline mouse model of essential tremor. Mov. Disord., 2006, 21(10), 1641-1649.
[http://dx.doi.org/10.1002/mds.20940] [PMID: 16773639]
[101]
Eder, U.; Leitner, B.; Kirchmair, R.; Pohl, P.; Jobst, K.A.; Smith, A.D.; Málly, J.; Benzer, A.; Riederer, P.; Reichmann, H.; Saria, A.; Winkler, H. Levels and proteolytic processing of chromogranin A and B and secretogranin II in cerebrospinal fluid in neurological diseases. J. Neural Transm. (Vienna), 1998, 105(1), 39-51.
[http://dx.doi.org/10.1007/s007020050036] [PMID: 9588759]
[102]
Alonso-Navarro, H.; Jiménez-Jiménez, F.J.; García-Martín, E.; Agúndez, J.A.G. Neurochemistry and neuropharmacology of essential tremor. e-book.Frontiers in Clinical Drug Research - CNS and Neurological Disorders; Rhaman, A.U., Ed.; Bentham Science Publishers, 2013, Vol. 2, pp. 110-142.
[http://dx.doi.org/10.2174/9781608057757113020007]

Rights & Permissions Print Cite
Article Metrics
43
4
1
© 2024 Bentham Science Publishers | Privacy Policy